174 related articles for article (PubMed ID: 36402939)
1. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma.
Takahashi M; Takishita M; Yamazato Y; Kakinoki H; Udo K; Tobu S; Noguchi M
CEN Case Rep; 2023 May; 12(2):237-241. PubMed ID: 36402939
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.
Kobayashi Y; Arai H; Honda M
Curr Oncol; 2020 Aug; 27(4):225-228. PubMed ID: 32905370
[TBL] [Abstract][Full Text] [Related]
3. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Ueda K; Suekane S; Kurose H; Ito N; Ogasawara N; Hiroshige T; Chikui K; Ejima K; Uemura K; Nakiri M; Nishihara K; Igawa T
Jpn J Clin Oncol; 2022 May; 52(5):479-485. PubMed ID: 35141749
[TBL] [Abstract][Full Text] [Related]
4. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.
Shaw LK; Wiele AJ; Sircar K; Wood CG; Msaouel P
Cancer Treat Res Commun; 2021; 27():100349. PubMed ID: 33725559
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
6. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
7. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
[TBL] [Abstract][Full Text] [Related]
8. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
[TBL] [Abstract][Full Text] [Related]
9. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
George G; Schmidt L; Tolat P; Riese M; Kilari D
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy].
Toyoshima M; Ikarashi D; Tsuboi H; Moriwaka M; Tamada S; Matsuura T; Maekawa S; Kato R; Kanehira M; Takata R; Sugimura J; Obara W
Hinyokika Kiyo; 2023 Aug; 69(8):227-232. PubMed ID: 37667600
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
[TBL] [Abstract][Full Text] [Related]
13. Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma.
Iwaki T; Niimi A; Kano M; Kurokawa Y; Yoshizaki U; Nozaki K; Nomiya A; Miyazaki H; Kume H
IJU Case Rep; 2021 Jan; 4(1):32-35. PubMed ID: 33426493
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Metachronous Occurrence of Interstitial Pneumonitis and Hypophysitis Following Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma].
Hayase T; Washino S; Mayumi S; Yazaki K; Nakamura Y; Oshima M; Konishi T; Saito K; Miyagawa T
Hinyokika Kiyo; 2021 Jun; 67(6):239-243. PubMed ID: 34265899
[TBL] [Abstract][Full Text] [Related]
16. Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.
Kobari Y; Yoshida K; Iizuka J; Kondo T; Ishida H; Tanabe K; Takagi T
In Vivo; 2021; 35(6):3585-3589. PubMed ID: 34697199
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
[TBL] [Abstract][Full Text] [Related]
19. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
[TBL] [Abstract][Full Text] [Related]
20. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
[No Abstract] [Full Text] [Related]
[Next] [New Search]